HF medication was well established with 213 (93%), 217 (95%) and 180 (79%) patients receiving therapy with renin-angiotensin-system blockers, beta-blockers, and mineralocorticoid receptor antagonists, respectively. The gene discussed is NR3C2; the disease is hydrops fetalis.